Target intelligence / Profile preview

RNA-binding protein Nova-2 (NOVA2)

Target
NOVA2
Molecular classification
RNA-binding protein, Alternative splicing regulator, KH-type splicing factor
01

Overview

RNA-binding protein Nova-2 (NOVA2) is a neuron-specific alternative splicing regulator that binds pre-mRNA in a sequence-specific manner, primarily in the central nervous system. It controls the expression of hundreds of different mRNA isoforms by modulating alternative exon inclusion or exclusion and is especially active during neural development. NOVA2 preferentially binds to YCAY motifs in intronic regions, playing a pivotal role in axonal guidance, neuronal migration, and cortical development by governing the splicing of genes involved in these pathways. Additionally, NOVA2 is the first RNA-binding protein known to globally promote circRNA biogenesis in the developing brain, with cell-type-specific effects on circRNA expression. NOVA2 is a well-conserved protein across species and shares high homology with Nova-1, another neural splicing regulator. It is not currently considered a direct therapeutic target or receptor for any approved drug, but autoantibodies against NOVA2 are an established biomarker for certain paraneoplastic neurological disorders. Loss or dysfunction of NOVA2 causes profound defects in neural development and may contribute to some human neurodevelopmental disorders.

Other names
NOVA alternative splicing regulator 2ANOVANOVA3Nova-2Astrocytic NOVA1-like RNA-binding proteinNeuro-oncological ventral antigen 2Neuro-oncological ventral antigen 3NEDASB
02

Biological functions

Alternative splicing regulationRegulation of circRNA biogenesismRNA metabolismNeuron differentiationAxonal guidance and outgrowthNeuronal migration
03

Disease associations

Neurodevelopmental disorder (with or without autistic features)Paraneoplastic neurologic disorder (implicated as an autoantigen in paraneoplastic opsoclonus-myoclonus ataxia, POMA)Potential role in neurodevelopmental and neuropsychiatric diseases
04

Safety considerations

Loss of function causes severe neurodevelopmental phenotypes in model organisms, including defect in axonal pathfinding, agenesis of the corpus callosum, and impaired neuronal migrationAs an autoantigen, immune targeting may cause CNS dysfunction
05

Biomarkers

Autoantibody marker in paraneoplastic neurologic disorders (POMA)

Beyond the preview

Go deeper on RNA-binding protein Nova-2 (NOVA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA-binding protein Nova-2 (NOVA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call